The first-in-class anti-cancer agent ABTL0812 is effective in preclinical models of human endometrial cancer.

Eva Colas,Nuria Eritja,Pau Muñoz-Guardiola,Sònia Solé-Sánchez,Cristian P. Moiola,Isidre Felip,Antonio Gil-Moreno,Héctor Pérez-Montoyo,Jose Alfon,Carles Domenech,Jose M. Lizcano,Xavier Matias-Guiu

The first-in-class anti-cancer agent ABTL0812 is effective in preclinical models of human endometrial cancer.

2017

Eva Colas
Nuria Eritja
Pau Muñoz-Guardiola
Sònia Solé-Sánchez
Cristian P. Moiola
Isidre Felip
Antonio Gil-Moreno
Héctor Pérez-Montoyo
Jose Alfon
Carles Domenech
Jose M. Lizcano
Xavier Matias-Guiu

e17070Background: ABTL0812 is a first-in-class anti-cancer agent with a unique mechanism of action currently in Phase Ib/IIa clinical development for endometrial cancer and squamous NSCLC. ABTL0812...

Keywords:

Cancer
Pathology
Endometrial cancer
Medicine
Oncology
Internal medicine
Mechanism of action

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations